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Summary The GI-101 human breast tumour xenograft line is unique in that it spontaneously metastasises to
the lungs of athymic murine hosts from subcutaneous trochar implants. Both tumour and lung metastases are
positive for normal human breast tissue markers. GI-101 also is positive for the p53 antigen but negative for
the c-erbB-2 oncogene.
Human breast cancers have proved to be among the most
difficult tumours to grow in immunodeficient mice. Two large
scale attempts to establish human breast tumour xenograft
lines from fresh tumour specimens have been successful for
only 6.5% of 433 specimens (Giovanella et al., 1991) and 9%
of 93 specimens (Fogh et al., 1982), with no evidence of
metastatic growth reported.
This report describes a human breast tumour xenograft
line originating directly from the patient specimen which
consistently metastasises to the lungs of athymic nude mouse
hosts (Hurst et al., 1991).
Materials and methods
Human mammary tumour xenograft line
The mammary tumour line (GI-101) was derived from a local
first recurrence of an infiltrating ductal adenocarcinoma
(Stage Illa, T3N2MX) in a 57 year old female who had not
received any therapy other than surgery. The tumour was
implanted by trochar in 3-5mm3 pieces subcutaneously to
the subaxial area of 12 week old (NCr) athymic nude female
mice. The GI-101 tumour line has been maintained for the
past 8 years by serial trochar transplant from 1,500-2,000
mm3 tumours.
Recipient animals are kept in a pathogen free environment
and are negative for pathogenic murine bacteria and viruses.
All husbandry and experimental procedures are performed
under a Class B laminar flow hood. Tumour histology and
lung metastases are monitored for each transplant genera-
tion.
Animals are maintained according to ILAR guidelines. All
procedures involving animals are performed according to
protocols approved by the Animal Care and Use Committee
at the GICR in compliance with PHS guidelines on Animal
Welfare Assurance.
Measurements ofprimary tumour
Xenografted subcutaneous tumours were measured once
weekly by vernier caliper and the volume calculated as a
hemi-elipsoid using the formula 0.5 (length x width x thick-
ness).
Immunohistochemistry
All immunohistochemistry (except for (ER) oestrogen recep-
tors and (PR) progesterone receptors) was performed on
neutral, buffered formalin fixed, paraffin-embedded tissues.
Immunostaining with Mabs was performed with the Vecta-
stain Elite ABC kit with DAB as the chromogen. Endo-
genous murine IgG did not cause significant background
staining when using formalin-fixed, paraffin embedded sec-
tions. ER and PR receptors were detected with Abbott and
CAS., Inc. kits, respectively.
Flow cytometric DNA profiles
Single parameter flow cytometric analysis was performed as
previously described (Schiano et al., 1991). Briefly, mechan-
ically-disrupted or enzyme-dissociated cells were stripped of
cytoplasm with a detergent and DNA stained with propidium
iodide. An EPICS 541 Flow Cytometer (Coulter Corp.) with
an argon laser was used to measure DNA. Twenty thousand
cells each, from GI-101 human breast tumour, mouse spleen
and human peripheral blood lymphocytes were analysed.
Results
Average growth rates of different transplant generations of
GI-101 are depicted in Figure 1. Individual tumour growth
rates within a single transplant generation group (5-10
animals) were variable although the size of tumour implants
was approximately the same. Whether this variability reflect-
ed differences in physiological status of the host and/or the
tumour implant remains to be determined.
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Figure 1 Growth rate of different transplant generations of GI-
101. Tumour volumes were calculated as 0.5 (length x width
x thickness). Standard errors of means are indicated at termina-
tion of each transplant line. Numbers within figure indicate trans-
plant generation. Each growth curve represents average tumour
volume of 5-10 animals.
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The GI-l01 xenograft line has remained consistent as a a
poorly differentiated mammary carcinoma with occasional
acinar and ductule formation (Figure 2a). The stromal com-
ponent is significant and in frozen sections stains intensely
for murine immunoglobulins. Although the tumours rarely
ulcerate, large tumours usually contain a necrotic core. Lung
metastases have been observed from the first transplant
generation and consist of multiple foci of undifferentiated
cells (Figure 2b). Of the specimens examined, metastatic lung
foci were rarely apparent until the subcutaneous implant had
grown to a volume of 500 mm3. Metastatic lung foci may
replace large segments of normal tissue by the time the
implant has grown to 2000 mm3. The size and number of
lung metastases are approximately proportional to tumour
size (data not shown). Tumour take rate is generally
100%.
Both breast tumour implant and lung metastases showed
strong affinity for Mabs to several breast tissue
differentiation antigens which are listed in Table I. Both
tissues also stained lightly to moderately positive for human b
cytokeratins (AEI/AE3), recombinant cathepsin-D, and the
tumour-associated antigens targeted by the Mabs1a5-6A,
B72.3 and p53. Primary tumour and metastases were negative
for nuclear proliferating antigen, breast cystic disease fluid,
carcinoembryonic antigen, 17-lA, and CC49 (a chimaeric
subclone of B72.3). Tumour and metastases were also
negative for both internal and external domains of c-erbB-2
oncoprotein and for ER and PR.
Control diploid human peripheral blood lymphocytes
generated DNA peaks at channels 80 (GI) and 157 (G2),
while control diploid mouse spleen cells showed DNA peaks
at channels 74 (GI) and 138 (G2) (Figure 3). A comparison
of histograms from GI-101 breast tumour and control histo-
grams demonstrates the presence of both murine and human
components. Breast tumour cells were all hyperploid, display-
ing GI phase DNA peaks at channels 98-100. The coeffi- h
cient of variation for channels was no more than ±3 chan- s t-
nels.
Figure 2 Histological appearance of GI-101 subcutaneous
tumour xenograft and lung metastases. Subcutaneous tumour a, Discussion and lung metastases b, at lOOX. Hematoxylin and Eosin stained
sections of transplant #17.
This report describes a unique human mammary tumour
xenograft line which metastasises to the lungs of athymic
nude mice. To our knowledge, this is the only human mam- Unlike breast tumour cell line implants, the breast tumour
mary tumour xenograft which undergoes spontaneous metas- xenograft line requires a relatively long lag period before
tases in an experimental host. Although a full characterisa- exponential growth is achieved and metastatic foci to the tion of the tumour line remains to be completed, it provides lungs become well established. The sequence of development
a unique opportunity to investigate the mechanism of metas- of metastatic foci in the lungs as well as possible occurrence tasis and test potential anti-metastatic therapies. of micrometastases in bone marrow and other sites is under
Table I Immunohistochemical reactivity of GI-101 human breast tumour and lung
metastases to monoclonal antibody markers
Primary Lung Antibody Antigen tumour metastases
AEl/AE3 (1) Human cytokeratin 8, 18 + + + + + +
EMA (2) Human epithelial membrane antigen + + + + + +
HMFG (1) Human milk fat globule membrane antigen + + + + + +
Cathespin-D (1) Recombinant Cathesin-D + + + +
H-23 (1) Mucin-like glycoprotein from breast + + + + + +
CB-1 1 (1) ErbB-2, internal domain - -
CB-El (1) ErbB-2, external domain - -
pl05 (1) Nuclear proliferating antigen - -
GCDFP (1) Breast cystic disease fluid - -
CEA (1) Carcinoembryonic antigen - -
15-6A (2) Breast tumour marker (non-specific) - -
17-1A (2) Colon tumour marker (non-specific) - -
B72.3 (2) Breast tumour marker (non-specific) + +
CCL4 (3) Subclone of B72.3
p53 (4) Oncogene associated protein + + +
(1) Courtesy of Dr M. Nadji, Department of Pathology, University of Miami, School of
Medicine. (2) Goodwin Institute. (3) Courtesy of Dr Jeff Schlom, Immunobiology, NCI. (4)
Courtesy of Dr William James, Oncor, Inc. All tissues were fixed in neutral, buffered
formalin, embedded in paraffin and stained via the Vectastain ABC Elite kit using DAB as a
chromogen.276 J. HURST et al.
HUMAN
PERIPHERAL MURINE
BLOOD SPLEEN
LYMPHOCYTES LYMPHOCYTES
BL BL
GL 80 157 GL 74 138
LPHCT BF-4 29/10/91 12:06 LPHCT -10 5/12/91 15:25
1P256 PT CON FN 170191 1P256 MOUSE SPLEEN0412
IRFL /IGFL, IRFL IRFL /IGFL, IRFL
CHANNEL 80 TO 157 INTEGRAL 8991 CHANNEL 70 TO 138 INTEGRAL 12072
PEAK 1708 AT 80 % IN INTERVAL 67.33 PEAK 3451 AT 71 % IN INTERVAL 59,86
UNTREATED GI-l01
FRESH POST ENZYMATIC
SPECIMEN DISSOCIATION
GI-101
Bl BL
GL 73 98 GL 75 100
HMT-2 -4 30/10/91 12:22 HMT-2 -5 30/10/91 12:38
1P256 BREAST FH 291091 1P256 BREAST DAYOATP
IRFL ,/IGFL, IRFL IRFL /IGFL, IRFL
CHANNEL 73 TO 98 INTEGRAL 1576 CHANNEL 75 TO 100 INTEGRAL 1940
PEAK 316 AT 98 % IN INTERVAL 37.09 PEAK 314 AT 100% IN INTERVAL 39.13
Figure 3 Single parameter DNA flow cytometric profiles of GI-101. DNA peaks of GI-101 before and after enzyme dissociation.
Normal human and murine lymphocytes are shown as controls. Peaks represent means for at least 20,000 cells.
study. Anaplastic lung metastases showed the same affinity
for normal breast tissue markers as the more differentiated
primary tumour.
The human genotype of the tumour has been ascertained
both by flow cytometric DNA profiles and positive immuno-
histostaining with Mabs against human breast tissue-associated
antigens, none of which cross reacted with control normal
murine tissues. GI-101 is negative for the c-erbB-2 oncogene,
but positive for p53. Mutation of the p53 gene (important in
the initial events controlling cell division) is the most com-
mon genetic change observed in breast and other cancers,
and is associated with a more aggressive phenotype (Harris,
1992).
DNA flow cytometry profiles of breast tumour showed
that it contains both murine and human components, the
tumour cells being mainly in the GI phase with a small
proportion in G2 and S phases. Although the diploid murine
cell population in this tumour has not been identified, Mab
against murine IgG in frozen sections was confined to the
tumour stroma, being completely absent in epithelium. Further
experiments designed to explore the above observations and
to evaluate the role of the murine stromal component in
xenograft growth and metastases are underway.
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